Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis

OBJECTIVE: Cerebrospinal fluid (CSF) biomarkers are shown to facilitate a risk identification of patients with mild cognitive impairment (MCI) into different risk levels of progression to Alzheimer’s disease (AD). Knowing a patient’s risk level provides an opportunity for earlier interventions, whic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacoecon Open
Hlavní autoři: Michaud, Tzeyu L., Kane, Robert L., McCarten, J. Riley, Gaugler, Joseph E., Nyman, John A., Kuntz, Karen M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2017
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6103924/
https://ncbi.nlm.nih.gov/pubmed/29623628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-017-0054-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky